期刊文献+

白血病干细胞介导的白血病耐药性及小白菊内酯的干预作用 被引量:3

下载PDF
导出
摘要 目的:分析白血病干细胞介导的白血病耐药性及小白菊内酯的干预作用。方法:以在我院确诊为急性髓系白血病的30例患者作为研究对象,应用免疫磁珠分选法分离白血病干细胞,并将获得的白血病干细胞分为试验组(白血病干细胞+小白菊内酯)和对照组(未加小白菊内酯),应用流式细胞仪检测两组中粘附分子CXCR4、CD62L、CD44、CD49d的蛋白表达情况。采用MTT法检测小白菊内酯对白血病干细胞增殖的抑制作用。结果:试验组白血病干细胞粘附分子CXCR4、CD62L、CD44、CD49d的蛋白表率明显低于对照组,细胞增殖的抑制率明显高于对照组,差异具有统计学意义(P<0.05)。结论:小白菊内酯可通过抑制白血病干细胞表面的粘附分子的表达,发挥促进白血病干细胞凋亡的作用。
出处 《北方药学》 2016年第1期124-125,共2页 Journal of North Pharmacy
  • 相关文献

参考文献5

二级参考文献129

  • 1陈腾,施靖华,赵荣华,李莉.胃癌患者手术前后淋巴细胞表型CD49 b、CD49 d的变化及其临床意义[J].临床和实验医学杂志,2006,5(5):457-458. 被引量:1
  • 2H6glund M, Sandin F, Hellstr6m K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry [J]. Blood, 2013, 122(7) :1284-1292.
  • 3Nasr R, Bazarbachi A. Chronic myeloid leukemia: "archetype"of the impact of targeted therapies[J]. Pathol Biol, 2012, 60 (4) :239-245.
  • 4Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and ST1571 (IRIS) [J]. Blood,2010,116 (19).. 3758-3765.
  • 5Castagnetti F, Palandri F, Amabile M, et al. Results of high- dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party[J]. Blood,2009,113(15) :3428- 3434.
  • 6Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia[J]. Curt Oncol, 2011,18 (2):71-83.
  • 7MOiler MC,Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations[J]. Blood, 2009, 114(24) :4944-4953.
  • 8Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia[J]. Blood, 2009,114(24) :4933-4938.
  • 9Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J]. N Engl J Med,2010,362(24) :2251-2259.
  • 10Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia[J]. N EnglJ Med,2010,362 (24): 2260-2270.

共引文献11

同被引文献37

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部